Events

EU Webinar: IP for Future and Emerging Technologies
APR
Tue
15
10:30 - 12:00

This was 7 months ago

Location

online

Programmes
HorizonEU L+F

Future and Emerging Technologies, (FETs) are those which are in early-stage commercialisation having recently left the lab. This webinar focusses on future and emerging technologies (FETs) and the insight that analysis of patenting activity can bring to the evolution of these technologies. Examples are chosen from EU initiatives such as Flagship projects amongst others.

Learning objectives:

  • emerging and disruptive technology definitions
  • how to identify FETs
  • basics of patent analytics
  • insights into selected FETs
  • resources for patent analytics

Registration and more information here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.